| U-M
Receives $14 Million Grant for Head and Neck Cancer Research
Chuck
Cote's voice is his livelihood. As a professional speaker,
he works with individuals to help them excel professionally
and personally by providing them with ways to conquer their
challenges. However, in May 2000, Mr. Cote (show on the right)
was faced with one of his greatest personal challenges that
not only threatened to end his career, but possibly his life
-- an advanced stage of throat cancer known as Squamus Cell
Carcinoma.
"When you hear those three words, 'you've
got cancer,' it just knocks you over," says Mr. Cote.
"And in the advanced stage my throat cancer was in, I
was told my only option was surgery that would cut away the
right side of my jaw and neck, causing me to lose the ability
to speak."
But he wasn't about to accept that fate. That's
when he came to the U-M Comprehensive Cancer Center and became
one of the participants in a new clinical trial involving
intensive chemotherapy and radiation in place of surgery.
Now, as a cancer survivor, Mr. Cote wants to
provide other head and neck cancer patients with hope and
a chance at a better quality of life. To make that happen,
he plans to work with researchers at the Cancer Center as
the patient advocate for a Specialized Program of Research
Excellence (SPORE) grant, which will allow physicians to identify
patients, like Mr. Cote, and treat them successfully without
surgery.
The five-year, $14 million SPORE grant was recently
awarded to the Cancer Center by the National
Cancer Institute. The NCI offered funding to a select
number of head and neck cancer researchers for the first time
this year in hopes of stimulating the movement of more laboratory
discoveries into the clinical settings for patient use.
With the SPORE grant, the Cancer Center will
work to significantly improve the diagnosis, treatment and
prevention of head and neck cancer. It also will advance the
use of chemotherapy for an innovative preservation treatment
approach pioneered by the Cancer Center, says Gregory
T. Wolf, M.D., professor and chair of the Department of
Otolaryngology -- Head and Neck Surgery at the U-M Health
System.
"Our overall goal with this grant is to
build upon our research and translate it into effective treatments
for our patients," says Dr. Wolf, who is the principal
investigator for the SPORE grant."We want to give people
a better quality of life by finding new ways to preserve the
structures in the mouth and throat affected by cancer."
The grant will fund a total of eight projects,
built upon preliminary clinical data. Each will be multidisciplinary
and collaborative efforts between the U-M departments of Radiation
Oncology, Otolaryngology, Pathology, Internal Medicine, the
Veterans Affairs Ann Arbor Healthcare System, the U-M School
of Dentistry and Henry Ford Hospital.
Through one of the projects, Mr. Cote's success
with the radiation/chemotherapy treatment will be closely
examined. His tumor, originally the size of an apple, was
shrunk by 90 percent in only 14 days using these methods.
"We'll actually be looking at the molecular
characteristics of Chuck's tumor in order to identify why
he did so well with this treatment,"explains Dr. Wolf.
"This will allow us to create specific treatments for
patients and avoid unnecessary treatments and surgery, if
possible."
More about head and neck cancer
About 40,000 Americans are affected by some form of head and
neck cancer, typically in the throat and mouth. Some of the
most common causes of head and neck cancer are smoking and
excessive alcohol consumption. Dr. Wolf says this form of
cancer is more common in men; however, in the past few years,
he's seen an increase in women, possibly due to expanded tobacco
use among that group.
In most cases, patients ignore their symptoms
-- a sore throat, hoarseness, difficulty swallowing, ear pain,
weight loss, and white or red patches in the mouth or throat
-- which often seem mild.
"I didn't think anything of my symptoms,"
says Mr. Cote, who believed his sore throat and ear ache were
the result of his career and a play in which he was performing.
"But in a matter of one week I went from thinking I just
had a sore throat to being diagnosed with cancer."
| 
Chuck Cote, pictured right, with Lance Armstrong
|
|
Since symptoms
are often ignored, patients tend to not come in for
treatment until the cancer is at an advanced stage,
which, Dr. Wolf says, gives the patient about a 50 percent
cure rate or less. Treatment in the past was limited
to surgery, or surgery with radiation. With surgery,
patients may lose part of their tongue, mouth or jaw.
But now, a combination of intense chemotherapy and radiation
at the U-M has helped increase the odds of survival
-- and the SPORE grant will work to further advance
treatment options.
"I always knew I'd make it through
this," says Mr. Cote. "I had an incredible
vision all while going through this treatment, that
I would go on to live a long and healthy life. Without
the Cancer Center clinical trial, I don't think I'd
be alive right now." |
return to top
|